demonstrated that the prognosis of patients having surgery for early-stage NS-NSCLC showing a KRAS G12C mutation had more recurrence than in cases of other KRAS mutation subtypes or KRAS wild-type tumors, thus opening the door in the future for potential adjuvant therapy targeting KRAS G12C [...
KRAS tumor mutations were detected in about 35% of patients; about 65% of patients had KRAS wild type tumors. KRAS mutation in colon ca blocks Cetuximab ELI-002 is an "AMP KRAS vaccine" containing seven Amphiphile mKRAS peptides and a proprietary Amphiphile adjuvant, administered subcutaneously....
To circumvent resistance mechanisms, researchers have investigated another mutation that leads to resistance to kinase inhibitors. RAS mutations, mainly HRAS and KRAS, lead to approximately 40% of sporadic MTC cases without RET mutations [115]. The remaining 20% of cases have no identified oncogenic...
[3]. Considering NSCLC, at the time of diagnosis, all advanced non-squamous NSCLC should be screened for EGFR (exon 18: G719x; exon 19: ex19del; exon 20: T790M, S768I, ex20ins; exon 21: L858R, L861Q), KRAS (G12C), BRAF (V600E), and HER2 mutations, for MET exon 14 ...
N2 disease is highly heterogeneous and may be subcategorized into “single-station”, “multi-station”, “bulky”, and “invasive”, leading to different diagnostic, staging, and treatment approaches. Staging definitions are currently being reevaluated due to the complex nature of N2 disease and ...